U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07391228) titled 'Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)' on Nov. 28, 2025.
Brief Summary: Pulmonary Arterial Hypertension (PAH) is a rare chronic disease marked by a pathological and sustained increase in pulmonary artery pressure as a result of structural and functional changes within the pulmonary vasculature. Beyond its cardiopulmonary manifestations, a growing body of evidence suggests that PAH may also affect cerebral hemodynamics and cognitive functioning as a consequence of prolonged reductions in cerebrovascular oxygenation potentially underlying the frontal-executive, attentional, and mnestic impairments reported in t...